InsightfulValue
← Home

GlaxoSmithKline
GlaxoSmithKline

Pharma / Pharma and biotechnology


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

πŸ“ Join us and grab your copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Overview
GlaxoSmithKline (GSK) is a multinational pharmaceutical and healthcare company headquartered in Brentford, London. The company was formed in 2000 through the merger of British company Glaxo Wellcome and American company SmithKline Beecham. It is one of the largest pharmaceutical companies in the world and is focused on the research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products.
History:
The history of GlaxoSmithKline can be traced back to the establishment of two independent companies: Joseph Nathan and Co. in New Zealand in 1873 and Burroughs Wellcome & Company in the UK in 1880. In 1995, Glaxo Wellcome PLC was formed through the merger of Glaxo and Burroughs Wellcome. SmithKline Beecham PLC was formed in 1989 through the merger of SmithKline Beckman Corporation and Beecham Group PLC. In 2000, the two companies merged to form GlaxoSmithKline.
Products:
GSK's product portfolio includes prescription medicines, vaccines, and consumer healthcare products. Its prescription medicines cover a broad range of therapeutic areas, including respiratory, HIV, oncology, and neurosciences. The company also offers vaccines for diseases such as influenza, meningitis, and shingles. Its consumer healthcare products include over-the-counter medicines, oral care, nutrition, and skin health products.
Research and Development:
GSK has a strong focus on research and development (R&D) and invests heavily in this area. The company has R&D facilities in the UK, US, Belgium, and China, among others. Its R&D efforts are focused on discovering and developing new medicines and vaccines for a wide range of diseases and conditions. GSK collaborates with academic institutions, governments, and other industry partners to advance its research efforts.
Corporate Responsibility:
GSK is committed to operating ethically and responsibly, with a focus on sustainability and corporate social responsibility. The company has various initiatives in place to reduce its environmental impact and improve access to healthcare for underserved populations. It also has policies in place to ensure ethical business practices and compliance with laws and regulations.
Financials:
In 2020, GSK reported revenues of Β£34 billion and a net income of Β£5.5 billion. The company employs over 100,000 people globally and has a presence in over 150 countries. Its primary stock exchange listings are on the London Stock Exchange and the New York Stock Exchange.
Partnerships:
GSK has formed partnerships with various organizations to further its research and development efforts, expand its product portfolio, and improve access to healthcare. Some notable collaborations include:
- Joint ventures with Pfizer in the areas of consumer healthcare and HIV treatment
- Collaboration with Sanofi to develop a COVID-19 vaccine
- Partnership with Innoviva to develop respiratory treatments
- Collaboration with Vir Biotechnology to develop pandemic treatments
- Partnership with the Bill & Melinda Gates Foundation to develop vaccines for malaria and tuberculosis
Summary:
GlaxoSmithKline is a multinational pharmaceutical and healthcare company focused on research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products. It has a strong history and presence in the market, with a commitment to corporate responsibility and ethical business practices. The company has a diverse range of products and partnerships that contribute to its strong financial performance.
What is special about the company?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlcmUgYX JlIHNldmVy YWwga2V5IG ZhY3RvcnMg dGhhdCBtYW tlIEdsYXhv U21pdGhLbG luZSAoR1NL KSBhIHVuaX F1ZSBhbmQg c3BlY2lhbC Bjb21wYW55 Ojxicj4xLi BTaXplIGFu ZCBTY29wZT ogR1NLIGlz IG9uZSBvZi B0aGUgbGFy Z2VzdCBwaG FybWFjZXV0 aWNhbCBjb2 1wYW5pZXMg aW4gdGhlIH dvcmxkLCB3 aXRoIG9wZX JhdGlvbnMg aW4gb3Zlci AxNTAgY291 bnRyaWVzIG FuZCBhIHZh c3QgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzIHNwYW5u aW5nIHByZX NjcmlwdGlv biBtZWRpY2 luZXMsIGNv bnN1bWVyIG hlYWx0aGNh cmUsIGFuZC B2YWNjaW5l cy48YnI+Mi 4gSGlzdG9y eSBhbmQgTG VnYWN5OiBH U0sgaGFzIG EgcmljaCBo aXN0b3J5IG RhdGluZyBi YWNrIHRvIH RoZSAxOXRo IGNlbnR1cn ksIHdpdGgg dGhlIG1lcm dlciBvZiBH bGF4b1dlbG xjb21lIGFu ZCBTbWl0aE tsaW5lIEJl ZWNoYW0gaW 4gMjAwMCBz b2xpZGlmeW luZyBpdHMg cG9zaXRpb2 4gYXMgYSBt YWpvciBwbG F5ZXIgaW4g dGhlIGhlYW x0aGNhcmUg aW5kdXN0cn kuPGJyPjMu IFJlc2Vhcm NoIGFuZCBE ZXZlbG9wbW VudDogSW5u b3ZhdGlvbi BhbmQgcmVz ZWFyY2ggYX JlIGF0IHRo ZSBoZWFydC BvZiBHU0sn cyBidXNpbm Vzcywgd2l0 aCBzaWduaW ZpY2FudCBp bnZlc3RtZW 50cyBtYWRl IGluIGRpc2 NvdmVyaW5n IGFuZCBkZX ZlbG9waW5n IG5ldyBtZW RpY2luZXMg dG8gbWVldC B1bm1ldCBt ZWRpY2FsIG 5lZWRzLjxi cj40LiBDb2 1taXRtZW50 IHRvIEdsb2 JhbCBIZWFs dGg6IEdTSy dzIG1pc3Np b24gaXMgdG 8gaW1wcm92 ZSB0aGUgcX VhbGl0eSBv ZiBodW1hbi BsaWZlIGJ5 IGVuYWJsaW 5nIHBlb3Bs ZSB0byBkby Btb3JlLCBm ZWVsIGJldH RlciwgYW5k IGxpdmUgbG 9uZ2VyLiBU aGUgY29tcG FueSBpcyBk ZWRpY2F0ZW QgdG8gYWRk cmVzc2luZy BnbG9iYWwg aGVhbHRoIG NoYWxsZW5n ZXMsIHN1Y2 ggYXMgaW5m ZWN0aW91cy BkaXNlYXNl cyBhbmQgYW NjZXNzIHRv IGhlYWx0aG NhcmUgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMuPG JyPjUuIERp dmVyc2UgUG 9ydGZvbGlv OiBHU0sgaG FzIGEgZGl2 ZXJzZSBwb3 J0Zm9saW8g b2YgcHJvZH VjdHMsIGlu Y2x1ZGluZy BtYXJrZXQt bGVhZGluZy BicmFuZHMg c3VjaCBhcy BBZHZhaXIs IFNlbnNvZH luZSwgYW5k IEZsb25hc2 UuIEl0IGFs c28gaGFzIG Egc3Ryb25n IHBpcGVsaW 5lIG9mIHBv dGVudGlhbC BuZXcgbWVk aWNpbmVzIG FuZCB2YWNj aW5lcyBpbi B2YXJpb3Vz IHN0YWdlcy BvZiBkZXZl bG9wbWVudC 48YnI+Ni4g Q29ycG9yYX RlIFJlc3Bv bnNpYmlsaX R5OiBHU0sg aXMgY29tbW l0dGVkIHRv IGNvbmR1Y3 RpbmcgYnVz aW5lc3Mgcm VzcG9uc2li bHkgYW5kIG V0aGljYWxs eSwgd2l0aC BhIGZvY3Vz IG9uIHN1c3 RhaW5hYmls aXR5LCBlbn Zpcm9ubWVu dGFsIHN0ZX dhcmRzaGlw LCBhbmQgaW 1wcm92aW5n IGFjY2Vzcy B0byBoZWFs dGhjYXJlIG ZvciB1bmRl cnNlcnZlZC Bwb3B1bGF0 aW9ucy48Yn I+Ny4gQ3Vs dHVyZSBhbm QgVmFsdWVz OiBHU0sgcH JpZGVzIGl0 c2VsZiBvbi BpdHMgZGl2 ZXJzZSBhbm QgaW5jbHVz aXZlIHdvcm twbGFjZSBj dWx0dXJlLC BndWlkZWQg YnkgYSBzZX Qgb2YgY29y ZSB2YWx1ZX MgdGhhdCBw cmlvcml0aX plIGludGVn cml0eSwgcm VzcGVjdCBm b3IgcGVvcG xlLCBhbmQg dHJhbnNwYX JlbmN5Ljxi cj5PdmVyYW xsLCBHU0sn cyBzaXplLC BoaXN0b3J5 LCBmb2N1cy BvbiBpbm5v dmF0aW9uIG FuZCBnbG9i YWwgaGVhbH RoLCBkaXZl cnNlIHBvcn Rmb2xpbywg Y29tbWl0bW VudCB0byBj b3Jwb3JhdG UgcmVzcG9u c2liaWxpdH ksIGFuZCBz dHJvbmcgY3 VsdHVyZSBt YWtlIGl0IG EgdW5pcXVl IGFuZCBlc3 RlZW1lZCBj b21wYW55IG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 4=
What the company's business model?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

R2xheG9TbW l0aEtsaW5l IChHU0spIG lzIGEgZ2xv YmFsIHBoYX JtYWNldXRp Y2FsIGFuZC BoZWFsdGhj YXJlIGNvbX BhbnkgZm9j dXNlZCBvbi BpbXByb3Zp bmcgdGhlIG hlYWx0aCBh bmQgd2VsbC 1iZWluZyBv ZiBwZW9wbG UgYXJvdW5k IHRoZSB3b3 JsZC4gVGhl IGNvbXBhbn kncyBidXNp bmVzcyBtb2 RlbCBpcyBi YXNlZCBvbi Bmb3VyIGtl eSBjb21wb2 5lbnRzOiA8 YnI+MS4gUm VzZWFyY2gg YW5kIERldm Vsb3BtZW50 IChSJkQpOi BHU0sgaW52 ZXN0cyBoZW F2aWx5IGlu IFImRCB0by BkZXZlbG9w IG5ldyBtZW RpY2luZXMs IHZhY2Npbm VzLCBhbmQg Y29uc3VtZX IgaGVhbHRo Y2FyZSBwcm 9kdWN0cy4g VGhlIGNvbX BhbnkgaGFz IHJlc2Vhcm NoIGNlbnRl cnMgYW5kIH BhcnRuZXJz aGlwcyB3b3 JsZHdpZGUg dG8gZHJpdm UgaW5ub3Zh dGlvbiBhbm QgaW1wcm92 ZSBwYXRpZW 50IGhlYWx0 aCBvdXRjb2 1lcy48YnI+ Mi4gQ29tbW VyY2lhbGl6 YXRpb24gYW 5kIE1hcmtl dGluZzogR1 NLIHNlbGxz IGl0cyBwcm 9kdWN0cyB0 byBwYXRpZW 50cywgaGVh bHRoY2FyZS Bwcm9mZXNz aW9uYWxzLC BhbmQgb3Ro ZXIgY3VzdG 9tZXJzIHRo cm91Z2ggYS B2YXJpZXR5 IG9mIGNoYW 5uZWxzLiBU aGlzIGluY2 x1ZGVzIHRy YWRpdGlvbm FsIHNhbGVz IGFuZCBtYX JrZXRpbmcg ZWZmb3J0cy wgYXMgd2Vs bCBhcyBkaW dpdGFsIGFu ZCBlLWNvbW 1lcmNlIGlu aXRpYXRpdm VzLjxicj4z LiBTdHJhdG VnaWMgUGFy dG5lcnNoaX BzOiBHU0sg Y29sbGFib3 JhdGVzIHdp dGggYSByYW 5nZSBvZiBw YXJ0bmVycy wgaW5jbHVk aW5nIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYmlv dGVjaCBjb2 1wYW5pZXMs IGFuZCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIH RvIGFkdmFu Y2UgaXRzIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCBlZmZvcn RzLjxicj40 LiBEaXZlcn NpZmllZCBQ b3J0Zm9saW 86IEdTSyBv cGVyYXRlcy BpbiB0aHJl ZSBtYWluIG FyZWFzIC0g cGhhcm1hY2 V1dGljYWxz LCB2YWNjaW 5lcywgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUuIF RoaXMgZGl2 ZXJzaWZpZW QgcG9ydGZv bGlvIGhlbH BzIG1pdGln YXRlIHJpc2 tzIGFuZCBh bGxvd3MgdG hlIGNvbXBh bnkgdG8gYm VuZWZpdCBm cm9tIHRoZS BkaWZmZXJl bnQgZ3Jvd3 RoIHRyZW5k cyBhbmQgcm VndWxhdG9y eSBsYW5kc2 NhcGVzIGFj cm9zcyB0aG VzZSBzZWN0 b3JzLjxicj 5JbiBhZGRp dGlvbiwgR1 NLIGhhcyBh IHN0cm9uZy Bmb2N1cyBv biBzdXN0YW luYWJpbGl0 eSBhbmQgc2 9jaWFsIHJl c3BvbnNpYm lsaXR5LCBp bnRlZ3JhdG luZyB0aGVz ZSBwcmluY2 lwbGVzIGlu dG8gaXRzIG J1c2luZXNz IG9wZXJhdG lvbnMgYW5k IGRlY2lzaW 9uLW1ha2lu Zy4gVGhlIG NvbXBhbnkg aXMgYWxzby Bjb21taXR0 ZWQgdG8gcH JpY2luZyBp dHMgcHJvZH VjdHMgcmVz cG9uc2libH kgYW5kIGVu c3VyaW5nIG FjY2VzcyB0 byBtZWRpY2 luZXMgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMu
Interesting facts about the company
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvbn VkRDBMNmt1 eFY4RFdsVX RKQjgud2Vi cCIgYWx0PS JHbGF4b1Nt aXRoS2xpbm UiIHRpdGxl PSJHbGF4b1 NtaXRoS2xp bmUiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2xh eG9TbWl0aE tsaW5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +ZjCBKb2lu IG5vdyB0by BnZXQgPGk+ IlRoZSBDaG Vja2xpc3Qg VmFsdWUgSW 52ZXN0b3Ig 4oCUIEEgU2 1hcnRlciBX YXkgdG8gUG ljayBTdG9j a3MiPC9pPi BhdCBubyBj b3N0CiAgIC AgICAgICAg ICAgICAgIC AgICAgIDwv cD4KCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDwh LS0KICAgIC AgICAgICAg ICAgICAgIC AgICAgPGRp diBzdHlsZT 0nbWFyZ2lu LXRvcDogMT JweDsgZm9u dC1zaXplOi AxM3B4OyBj b2xvcjogIz Q0NDsnPgog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgU2ln biB1cCBub3 cgYW5kIGdl dCBvdXIgZn JlZSBlQm9v ayAKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IDxiPlRoZS BDaGVja2xp c3QgVmFsdW UgSW52ZXN0 b3Ig4oCUIE EgU21hcnRl ciBXYXkgdG 8gUGljayBT dG9ja3M8L2 I+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPCEtLQ ogICAgICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdt YXJnaW4tdG 9wOiAxNnB4 OyBmb250LX NpemU6IDE0 cHg7IGNvbG 9yOiAjNDQ0 OyBmb250LW ZhbWlseTog LWFwcGxlLX N5c3RlbSwg QmxpbmtNYW NTeXN0ZW1G b250LCBTZW dvZSBVSSwg Um9ib3RvLC BIZWx2ZXRp Y2EgTmV1ZS wgc2Fucy1z ZXJpZjsgbG luZS1oZWln aHQ6IDEuNj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgSGF2ZSB5 b3UgaGVhcm QgYWJvdXQg b3VyIHNob3 J0IDxzdHJv bmcgc3R5bG U9J2ZvbnQt d2VpZ2h0Oi A2MDA7Jz5E YWlseSBWaW RlbyBOZXdz bGV0dGVyPC 9zdHJvbmc+ PwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGEgaHJlZj 0naHR0cHM6 Ly93d3cuaW 5zaWdodGZ1 bHZhbHVlLm NvbS9uZXdz bGV0dGVyLn BocCcgdGFy Z2V0PSdfYm xhbmsnIHN0 eWxlPSdjb2 xvcjogIzAw N0JGRjsgdG V4dC1kZWNv cmF0aW9uOi Bub25lOyBm b250LXdlaW dodDogNTAw OyBtYXJnaW 4tbGVmdDog NnB4Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgRmluZCBv dXQgbW9yZQ ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9hPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgLS 0+CiAgICAg ICAgICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgPC9k aXY+CiAgIC AgICAgICAg IAogICAgIC AgIAogICAg ICAgIDxzcG FuIGNsYXNz PSdibHVycm VkLXRleHQn PgogICAgIC AgICAgICBN UzRnUjJ4aG VHIDlUYlds MGFFdHMgYV c1bElHbHpJ RyBFZ1FuSn BkR2x6IGFD QnRkV3gwYV cgNWhkR2x2 Ym1GcyBJSE JvWVhKdFlX IE5sZFhScF kyRnMgSUdO dmJYQmhibi Brc0lIZHBk R2dnIGFHVm haSEYxWVgg SjBaWEp6SU dsdSBJRXh2 Ym1SdmJpIH dnUlc1bmJH RnUgWkM0OF luSStNaSA0 Z1ZHaGxJR0 52IGJYQmhi bmtnYUcgRn pJR0VnYkc5 dSBaeUJvYV hOMGIzIEo1 TENCa1lYUn AgYm1jZ1lt RmpheSBCMG J5QmhJSEJv IFlYSnRZV0 41SUcgOXda VzVsWkNCaS BlU0JLYjNO bGNHIGdnVG 1GMGFHRnUg SUdsdUlFNW xkeSBCYVpX RnNZVzVrIE lHbHVJREU0 TXogQXVQR0 p5UGpNdSBJ RlJvWlNCam IyIDF3WVc1 NUlIZGggY3 lCbWIzSnRZ VyB4c2VTQm 1iM1Z1IFpH VmtJR2x1SU QgRTVNRFln WW5rZyBTbT l6WlhCb0lF IFZrZDJGeV pDQk8gWVhS b1lXNGdZVy A1a0lHaHBj eUJpIGNtOT BhR1Z5TFcg bHVMV3hoZH l3ZyBWR2h2 YldGeklFIG h2Ykd4dmQy RjUgTENCaG N5QmhJSCBO dFlXeHNJSE JvIFlYSnRZ V041SUcgbH VJRXh2Ym1S diBiaTQ4WW 5JK05DIDRn VkdobElHNW ggYldVZ1Iy eGhlRyA4Z1 kyOXRaWE1n IFpuSnZiU0 IwYUcgVWda bWx5YzNRZy BjSEp2WkhW amRDIEIwYU dGMElIUm8g WlNCamIyMX dZVyA1NUlI QnliMlIxIF kyVmtMQ0Iz YUcgbGphQ0 IzWVhNZyBZ U0JrY21sbF pDIEJ0YVd4 cklIQnkgYj JSMVkzUWdZ MiBGc2JHVm tJRWRzIFlY aHZManhpY2 ogNDFMaUJI YkdGNCBieU J0WlhKblpX IFFnZDJsMG FDQlggWld4 c1kyOXRaUy BCcGJpQXhP VGsxIElIUn ZJR1p2Y20g MGdSMnhoZU c4ZyBWMlZz YkdOdmJXIF VzSUhkb2FX Tm8gSUhSb1 pXNGdiVyBW eVoyVmtJSG RwIGRHZ2dV MjFwZEcgaE xiR2x1WlNC QyBaV1ZqYU dGdElHIGx1 SURJd01EQW cgZEc4Z1pt OXliUyBCSG JHRjRiMU50 IGFYUm9TMn hwYm0gVXVQ R0p5UGpZdS BJRWRzWVho dlUyIDFwZE doTGJHbHUg WlNCcGN5Qm pkWCBKeVpX NTBiSGtnIG IyNWxJRzlt SUggUm9aU0 JzWVhKbiBa WE4wSUhCb1 lYIEp0WVdO bGRYUnAgWT JGc0lHTnZi WCBCaGJtbG xjeUJwIGJp QjBhR1VnZD IgOXliR1Fz SUhkcCBkR2 dnY21WMlpX IDUxWlNCdl ppQnYgZG1W eUlDUTBNUy BCaWFXeHNh Vzl1IElHbH VJREl3TWog QXVQR0p5UG pjdSBJRlJv WlNCamIyID F3WVc1NUlH bHogSUdFZ2 JXRnFiMyBJ Z2NISnZaSF ZqIFpYSWdi MllnZG0gRm pZMmx1WlhN cyBJR052Ym 5OMWJXIFZ5 SUdobFlXeD AgYUdOaGNt VWdjSCBKdl pIVmpkSE1z IElHRnVaQ0 J3Y20gVnpZ M0pwY0hScC BiMjRnYldW a2FXIE5wYm 1WekxDQmgg Ym1RZ2FYUW dhRyBGeklH RWdjSEpsIG MyVnVZMlVn YVcgNGdiM1 psY2lBeCBO VEFnWTI5MW JuIFJ5YVdW ekxqeGkgY2 o0NExpQkhi RyBGNGIxTn RhWFJvIFMy eHBibVVnYU cgRnpJR0Vn Ykc5dSBaeU JvYVhOMGIz IEo1SUc5bU lITnAgWjI1 cFptbGpZVy A1MElITmph V1Z1IGRHbG 1hV01nWVcg Tm9hV1YyWl cxbCBiblJ6 TENCcGJtIE 5zZFdScGJt Y2cgZEdobE lHUmxkbSBW c2IzQnRaVz UwIElHOW1J SFJ5WlcgRj BiV1Z1ZEhN ZyBabTl5SU VoSlZpIHdn YVc1bWJIVm wgYm5waExD QmhibSBRZ2 JXRnNZWEpw IFlTNDhZbk krT1MgNGdW R2hsSUdOdi BiWEJoYm5r Z2FHIEZ6SU dGc2MyOGcg WW1WbGJpQn BibiBadmJI WmxaQ0JwIG JpQnpaWFps Y20gRnNJR2 hwWjJndCBj SEp2Wm1sc1 pTIEJzWldk aGJDQmogWV hObGN5d2dh VyA1amJIVm thVzVuIElH RWdKRE1nWW 0gbHNiR2x2 YmlCeiBaWF IwYkdWdFpX IDUwSUdadm NpQnAgYkd4 bFoyRnNiSC BrZ2NISnZi VzkwIGFXNW 5JR05sY24g UmhhVzRnWk hKMSBaM01n WVc1a0lHIE VnYzJWMGRH eGwgYldWdW RDQjNhWCBS b0lIUm9aU0 JWIFV5Qm5i M1psY20gNX RaVzUwSUda diBjaUFrTn pVd0lHIDFw Ykd4cGIyNG cgWm05eUlH MWhibiBWbV lXTjBkWEpw IGJtY2dZVz VrSUggRjFZ V3hwZEhrZy BZMjl1ZEhK dmJDIEJ3Y2 05aWJHVnQg Y3lCaGRDQm hJSCBCc1lX NTBJR2x1IE lGQjFaWEow YnkgQlNhV0 52TGp4aSBj ajR4TUM0Z1 NXIDRnTWpB eU1Dd2cgUj J4aGVHOVRi VyBsMGFFdH NhVzVsIElH SmxZMkZ0Wl MgQjBhR1Vn Wm1seSBjM1 FnY0doaGNt IDFoWTJWMW RHbGogWVd3 Z1kyOXRjRy BGdWVTQjBi eUJ3IGJHVm taMlVnZEcg OGdiV0ZyWl NCcCBkSE1n WTJGeVltID l1SUdadmIz UncgY21sdW RDQnVaWCBR dGVtVnlieU JpIGVTQXlN RFV3TGogeG ljajR4TVM0 ZyBSMnhoZU c5VGJXIGww YUV0c2FXNW wgSUdoaGN5 QmhJSCBOMG NtOXVaeUJq IGIyMXRhWF J0WlcgNTBJ SFJ2SUdOdi BjbkJ2Y21G MFpTIEJ6Yj JOcFlXd2cg Y21WemNHOX VjMiBsaWFX eHBkSGtzIE lIZHBkR2dn WVMgQm1iMk 4xY3lCdiBi aUJwYlhCeW IzIFpwYm1j Z1oyeHYgWW 1Gc0lHaGxZ VyB4MGFDd2 djbVZrIGRX TnBibWNnYV ggUnpJR1Z1 ZG1seSBiMj V0Wlc1MFlX IHdnYVcxd1 lXTjAgTENC aGJtUWdjMy BWd2NHOXlk R2x1IFp5Qm piMjF0ZFcg NXBkR2xsY3 lCMyBhR1Z5 WlNCcGRDIE J2Y0dWeVlY UmwgY3k0OF luSStNVCBJ dUlGUm9aU0 JqIGIyMXdZ VzU1SUcgaG hjeUJoSUdS cCBkbVZ5Yz JVZ2QyIDl5 YTJadmNtTm wgTENCM2FY Um9JRyA5Ml pYSWdNVEF3 IExEQXdNQ0 JsYlggQnNi M2xsWlhNZy BkMjl5YkdS M2FXIFJsSU dGdVpDQmgg SUhOMGNtOX VaeSBCbWIy TjFjeUJ2IG JpQmthWFps Y24gTnBkSG tnWVc1ayBJ R2x1WTJ4MW MyIGx2YmlC cGJpQjAgYU dVZ2QyOXlh MyBCc1lXTm xManhpIGNq NHhNeTRnUj IgeGhlRzlU YldsMCBhRX RzYVc1bElH IGhoY3lCaE lISnYgWW5W emRDQndhWC BCbGJHbHVa U0J2IFppQn VaWGNnWkgg SjFaM01nWV c1ayBJSFJ5 WldGMGJXIF Z1ZEhNZ2FX NGcgWkdWMl pXeHZjRyAx bGJuUXNJSG RwIGRHZ2di M1psY2kgQT FNQ0JqWVc1 ayBhV1JoZE dVZ2RHIGhs Y21Gd2FXVn ogSUdsdUlI WmhjbSBsdm RYTWdjM1Jo IFoyVnpJRz ltSUcgTnNh VzVwWTJGcy BJSFJ5YVdG c2N5IDQ4WW 5JK01UUXUg SUZSb1pTQm piMiAxd1lX NTVJR2hoIG N5QmhJSE4w Y20gOXVaeU J3Y21WeiBa VzVqWlNCdm JpIEJ6YjJO cFlXd2cgYl dWa2FXRXNJ SCBkcGRHZ2 diM1psIGNp QTROU3d3TU QgQWdabTlz Ykc5MyBaWE p6SUc5dUlG IFIzYVhSMF pYSWcgWVc1 a0lHRmpkRy BsMlpTQmhZ Mk52IGRXNT BjeUJ2Ymkg Qk1hVzVyWl dSSiBiaXdn Um1GalpXIE p2YjJzc0lH RnUgWkNCSm JuTjBZVyBk eVlXMHVQR0 p5IFBqRTFM aUJIYkcgRj RiMU50YVhS byBTMnhwYm 1VZ2FHIEZ6 SUhKbFkyVn AgZG1Wa0lH NTFiVyBWeW IzVnpJR0Yz IFlYSmtjeU JoYm0gUWdj bVZqYjJkdS BhWFJwYjI0 Z1ptIDl5SU dsMGN5QjMg YjNKckxDQn BibSBOc2RX UnBibWNnIF ltVnBibWNn Ym0gRnRaV1 FnYjI1bCBJ RzltSUhSb1 pTIERpZ0p4 WGIzSnMgWk 9LQW1YTWdU VyA5emRDQk ZkR2hwIFky RnNJRU52Yl ggQmhibWxs YytLQSBuU0 JpZVNCMGFH IFVnUlhSb2 FYTncgYUdW eVpTQkpibi BOMGFYUjFk R1VnIFptOX lJREV4SUcg TnZibk5sWT NWMCBhWFps SUhsbFlYIE p6TGc9PQog ICAgICAgID wvc3Bhbj4K ICAgICAgIC AKICAgICAg ICA=
See Company Q&A
GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal